• metastatic/advanced OC (mOC) - maintenance (M) 2
• pancreatic ductal adenocarcinoma
• PIK3CA-related overgrowth spectrum
• prostate cancer (PC)

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• avelumab based treatment
• avelumab plus SoC
• nivolumab based treatment
• poly ADP-ribose polymerase (PARP) inhibitor
• rucaparib

• versus all
• vs chemotherapy
• vs Standard of Care (SoC)
• vs poly ADP-ribose polymerase (PARP) inhibitor
• vs rucaparib

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Pathology:  metastatic/advanced OC (mOC) - maintenance (M);